Enzon, which develops and commercializes therapeutics for life-threatening diseases, is relocating its headquarters from nearby Piscataway, NJ. The move marks an expansion for the company, which will continue to maintain its R&D operations in Piscataway. Both operations are currently housed at the latter site.
The tenant was represented in the transaction by Thomas V. Giannone, senior vice president of Julien J. Studley Inc. of New Jersey. Jonathan Kushner, director of leasing for Schenkman/Kushner, represented the ownership. Terms and details of the transaction were not disclosed.
"By securing a second location in close proximity to its existing facility, Enzon has been able to enhance its current operations and position itself for further expansion," according to Giannone.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.